There are many major acquisition of small biotech firm and collaboration in the space of AML with some examples below:
https://www.biopharmadive.com/news/japanese-pharma-snaps-up-cancer-biotech-tolero/432921/
Japanese pharmaco Sumitomo Dainippon Pharma has picked up oncology and hematology biotech Tolero Pharmaceuticals for up to $780 million. This includes, with an upfront payment of $200 million, development milestones of up to $430 million, and commercial payments of up to $150 million.
https://www.genengnews.com/topics/translational-medicine/cephalon-makes-231m-overall-bid-to-acquire-chemgenex-for-nda-ready-cml-drug/81244891/
Cephalon Makes $231M Overall Bid to Acquire ChemGenex for NDA-Ready CML Drug
Celator bought for 1.5 billion by jazz. https://www.mdanderson.org/newsroom/2018/08/md-anderson-jazz-pharmaceuticals-collaborate-to-evaluate-options-for-hematologic-malignancies.html
Look forward to see this happens to PTX in 2019.
